Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Public Equity Report: Insmed, Merus raise combined $1B+ after readouts

Plus: PIPEs help Celcuity, Cargo advance clinical programs

May 31, 2024 10:20 PM UTC

On the strength of clinical results, Insmed and Merus each priced follow-ons to raise more than $1 billion combined this week, while Celcuity and Cargo each refilled the till with PIPEs.

Insmed Inc. (NASDAQ:INSM) raised $650 million in an upsized public offering that closely followed its Phase III readout for brensocatib to treat bronchiectasis. The CTSC inhibitor significantly reduced pulmonary exacerbations compared with placebo in the ASPEN study, meeting its primary endpoint...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article